Research programme: asthma and COPD therapy - GlaxoSmithKline

Drug Profile

Research programme: asthma and COPD therapy - GlaxoSmithKline

Alternative Names: I-kappa-B kinase inhibitors research programme - GlaxoSmithKline; IKK-2 inhibitors research programme - GlaxoSmithKline

Latest Information Update: 17 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Jun 2005 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
  • 21 Jun 2005 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
  • 21 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Respiratory Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top